Skip to content
Nonprofiteer
← FOUNDATION FOR INNOVATIVE NEW DIAGNOSTICS FIND

Form 990 for tax year 2022

Filed by FOUNDATION FOR INNOVATIVE NEW DIAGNOSTICS FIND.

Totals

Total revenue
$144,248,069
Total expenses
$146,186,498
Contributions and grants received
$142,991,509
Grants paid
$87,636,841
Program service revenue
$0
Investment income
$961,319
Other revenue
$295,241
Total assets, end of year
$137,542,319
Total liabilities, end of year
$115,874,802
Net assets or fund balances, end of year
$21,667,517
Program services expenses (Part IX)
$135,321,873
Management and general expenses
$10,058,716
Fundraising expenses
$805,909
Program service expenses (Part III)
$135,321,873

Program services were 92.6% of total expenses calculated — Part IX's program-services column over total expenses, both as filed.

Line items

Every line the filer filed in Parts VIII, IX and X, as filed and in filed order. Blank columns are left out, and the lines are not forced to add up to the totals above.

Revenue

Part VIII, the statement of revenue.

  • 1e · Government grants (contributions)

    $118,426,164

  • 1f · All other contributions, gifts and grants

    $24,565,345

  • 3 · Investment income

    total $961,319 · excluded $961,319

  • 4 · Income from investment of tax-exempt bond proceeds

    total $0

  • 5 · Royalties

    total $0

  • 6c · Rental income or loss

    real property $0 · personal property $0

  • 6d · Net rental income or loss

    total $0

  • 7d · Net gain or loss

    total $0

  • 8a · Fundraising events: gross income

    $0

  • 8b · Fundraising events: direct expenses

    $0

  • 8c · Net income from fundraising events

    total $0

  • 9a · Gaming: gross income

    $0

  • 9b · Gaming: direct expenses

    $0

  • 9c · Net income from gaming

    total $0

  • 10a · Gross sales of inventory

    $0

  • 10b · Cost of goods sold

    $0

  • 10c · Net income from sales of inventory

    total $0

  • 11a · Other revenue: COMMISSION ON TAX DEDUCTION

    total $35,133 · excluded $35,133

  • 11b · Other revenue: OTHER INCOME

    total $260,108 · excluded $260,108

  • 11e · Other revenue, total

    $295,241

Functional expenses

Part IX, the statement of functional expenses.

  • 1 · Grants to domestic organizations and governments

    total $17,751,551 · program services $17,751,551

  • 2 · Grants to domestic individuals

    total $0

  • 3 · Grants to foreign organizations and individuals

    total $69,885,290 · program services $69,885,290

  • 4 · Benefits paid to or for members

    total $0

  • 5 · Compensation of officers, directors and key employees

    total $2,467,485 · program services $1,550,803 · management and general $751,482 · fundraising $165,200

  • 6 · Compensation of disqualified persons

    total $0

  • 7 · Other salaries and wages

    total $15,627,720 · program services $12,300,226 · management and general $3,095,379 · fundraising $232,115

  • 8 · Pension plan contributions

    total $1,381,101 · program services $1,041,902 · management and general $329,343 · fundraising $9,856

  • 9 · Other employee benefits

    total $925,049 · program services $553,348 · management and general $362,165 · fundraising $9,536

  • 10 · Payroll taxes

    total $1,514,784 · program services $1,173,415 · management and general $317,325 · fundraising $24,044

  • 11a · Fees: management

    total $1,269,424 · program services $459,351 · management and general $810,073

  • 11b · Fees: legal

    total $79,120 · program services $3,787 · management and general $75,333

  • 11c · Fees: accounting

    total $320,359 · program services $144,228 · management and general $176,131

  • 11d · Fees: lobbying

    total $0

  • 11e · Fees: professional fundraising services

    total $0

  • 11f · Fees: investment management

    total $0

  • 11g · Fees: other

    total $14,785 · program services $314 · management and general $14,471

  • 12 · Advertising and promotion

    total $0

  • 13 · Office expenses

    total $1,758,474 · program services $1,706,948 · management and general $51,526

  • 14 · Information technology

    total $1,936,196 · program services $1,346,149 · management and general $590,047

  • 15 · Royalties

    total $0

  • 16 · Occupancy

    total $955,401 · program services $16,997 · management and general $938,404

  • 17 · Travel

    total $2,329,044 · program services $2,071,757 · management and general $227,403 · fundraising $29,884

  • 18 · Travel or entertainment for public officials

    total $0

  • 19 · Conferences, conventions and meetings

    total $403,211 · program services $307,968 · management and general $95,243

  • 20 · Interest

    total $0

  • 21 · Payments to affiliates

    total $0

  • 22 · Depreciation, depletion and amortization

    total $4,461 · management and general $4,461

  • 23 · Insurance

    total $83,374 · program services $11,995 · management and general $71,379

  • 24a · Other expenses: PROJECT CONTRACTORS

    total $19,812,475 · program services $18,427,047 · management and general $1,050,154 · fundraising $335,274

  • 24b · Other expenses: EQUIPMENT & SUPPLIES

    total $6,687,856 · program services $6,525,392 · management and general $162,464

  • 24c · Other expenses: TRANSLATION & SPONSORSHIP

    total $69,170 · program services $43,405 · management and general $25,765

  • 24d · Other expenses: FOREIGN EXCHANGE LOSSES

    total $910,168 · management and general $910,168

Balance sheet

Part X, book values.

  • 1 · Cash, non-interest-bearing

    beginning of year $22,817,170 · end of year $39,489,542

  • 2 · Savings and temporary cash investments

    beginning of year $123,146,860 · end of year $81,401,662

  • 3 · Pledges and grants receivable

    beginning of year $0 · end of year $0

  • 4 · Accounts receivable

    beginning of year $13,930,408 · end of year $7,215,019

  • 5 · Loans and receivables from officers and key people

    beginning of year $0 · end of year $0

  • 6 · Loans and receivables from disqualified persons

    beginning of year $0 · end of year $0

  • 7 · Other notes and loans receivable

    beginning of year $0 · end of year $0

  • 8 · Inventories for sale or use

    beginning of year $0 · end of year $0

  • 9 · Prepaid expenses and deferred charges

    beginning of year $29,389,709 · end of year $9,166,796

  • 10a · Land, buildings and equipment: cost or other basis

    $76,320

  • 10b · Land, buildings and equipment: accumulated depreciation

    $76,320

  • 10c · Land, buildings and equipment, net

    beginning of year $4,461 · end of year $0

  • 11 · Investments: publicly traded securities

    beginning of year $0 · end of year $0

  • 12 · Investments: other securities

    beginning of year $0 · end of year $0

  • 13 · Investments: program-related

    beginning of year $0 · end of year $0

  • 14 · Intangible assets

    beginning of year $0 · end of year $0

  • 15 · Other assets

    beginning of year $218,509 · end of year $269,300

  • 17 · Accounts payable and accrued expenses

    beginning of year $9,499,354 · end of year $19,116,387

  • 18 · Grants payable

    beginning of year $0 · end of year $0

  • 19 · Deferred revenue

    beginning of year $157,963,445 · end of year $96,758,415

  • 20 · Tax-exempt bond liabilities

    beginning of year $0 · end of year $0

  • 21 · Escrow or custodial account liability

    beginning of year $0 · end of year $0

  • 22 · Loans and payables to officers and key people

    beginning of year $0 · end of year $0

  • 23 · Secured mortgages and notes payable

    beginning of year $0 · end of year $0

  • 24 · Unsecured notes and loans payable

    beginning of year $0 · end of year $0

  • 25 · Other liabilities

    beginning of year $0 · end of year $0

  • 27 · Net assets without donor restrictions

    beginning of year $6,008,808 · end of year $12,607,693

  • 28 · Net assets with donor restrictions

    beginning of year $16,035,510 · end of year $9,059,824

Mission and programs · 2022

Mission

FIND IS AN INTERNATIONAL NON-PROFIT ORGANIZATION THAT ENABLES THE DEVELOPMENT AND DELIVERY OF MUCH-NEEDED DIAGNOSTIC TESTS FOR POVERTY-RELATED DISEASES. FIND ACTS AS A BRIDGE BETWEEN EXPERTS IN TECHNOLOGY DEVELOPMENT, POLICY AND CLINICAL CARE, REDUCING BARRIERS TO INNOVATION AND EFFECTIVE IMPLEMENTATION OF DIAGNOSTIC SOLUTIONS IN LOW-AND-MIDDLE-INCOME COUNTRIES.

Activities or mission (Part I)

The development and implementation of new, low cost diagnostics for infectious diseases for use in low- resource areas.

  • COVID-19 EXPENDITURE USD 103,061,587 FIND's 2022 COVID-19 activities addressed access inequities as well as diagnostics research and development (R&D). FIND led major advances in regional diagnostics manufacturing and evaluated more than 50 COVID-19 tests. Investments led directly to manufacturing capacity based in low- and middle-income countries (LMICs) of 60 million COVID-19 rapid tests (RDTs) and self-tests per month, available to LMICs at US$1-2 per test. FIND's technology transfer programmes enabled Diatropix (Senegal) to manufacture high-quality COVID-19 RDTs and break ground on a new facility for low-cost, high-volume manufacturing for RDTs of regional importance. FIND supported Premier Medical Corporation (India) to expand production capacity to 10 million RDTs/month under global access terms. FIND enabled WAMA Diagnstica (Brazil) in the end-to-end manufacture of RDTs from raw materials. FIND's support enabled Wondfo Biotech (China) and Viatris (South Africa) to achieve WHO Emergency Use Listing (EUL) for their COVID-19 RDTs. Additionally, FIND's provision of independent trial data supported the WHO Emergency Use Listing (EUL) of six COVID-19 tests in 2022, and a seventh in 2023. FIND's assessment of COVID-19 Ag RDT performance included test accuracy and the ability to detect new variants. These studies have now encompassed 54 Ag RDTs, including professional use and self-tests. FIND monitored and mapped both testing and sequencing capacity for COVID-19, as well as tracking the impact of new variants of concern on test performance. FIND supported decentralized community-based testing for COVID-19 and test-and-treat strategies. FIND also generated data that helped in-country policy reviews on the use of Ag RDTs in settings beyond those recommended in the WHO guidelines, including pharmacy channels and non-traditional settings such as taxi ranks. FIND supported the procurement of 1,889,144 diagnostic tests and related consumables, of which 1,853,854 were COVID-19 Ag RDTs, while supporting the introduction of their use in 26 countries.

    Expenses $103,061,587 · Grants $72,311,140

  • Tuberculosis (TB) and hepatitis (HCV) EXPENDITURE USD 10,283,492 FIND initiated its first-ever comprehensive involvement of patients in study design, through the Unitaid-funded DriveDx4TB project to seek patient perspectives on novel sample types for TB diagnostics. In the recent development of a WHO target product profile (TPP) for TB, FIND developed an impact model that indicates that new point-of-care (POC) tests for TB that provide results to the patient during the same clinical visit would require minimum sensitivities of 59-70% and 65-71% for non-sputum and sputum samples, respectively, depending on the country and standard of care, to achieve comparable or better case detection than the current standard of care. To maximize value for money of newly developed TB diagnostics, FIND introduced evidence-based target pricing into the forthcoming TPP for TB diagnostics. This work provides a novel framework to guide the future development of TPPs for diagnostics. FIND supported 10 TB products (7 IVDs and 3 digital tools) across various stages of diagnostic product life cycle including 4 IVDs and 1 digital tool in the development phases. FIND also supported 3 HCV tests in the development phases. FIND led the development of targeted next-generation sequencing (tNGS) for use in patients with TB, and the data obtained from this three-country study form the backbone of a new WHO evidence review and guidelines for TB management. FIND identified and demonstrated lot-to-lot variability of the FujiLAM TB rapid test as an unanticipated outcome of a large, seven-country evaluation of the test's accuracy, supporting the WHO decision to cancel a policy review; FIND supported FujiFilm in conducting a root cause analysis and planning a redesigned test. An existing digital global good, developed by MedicMobile, was enhanced to allow for bidirectional TB and COVID-19 screening and NCD screening.

    Expenses $10,283,492 · Grants $3,528,906

  • Access EXPENDITURE USD 6,560,663 FIND and the Indonesian Ministry of Health (MoH) signed a memorandum of understanding (MoU) to expand access to essential diagnostics across 18,000 primary health centres throughout Indonesia, while enhancing pandemic surveillance and advancing diagnostics manufacturing in Indonesia. FIND entered a collaboration with the African Society for Laboratory Medicine (ASLM) and jointly launched the diagnostic network optimization sub-community of practice (DNO subCoP), under the overarching laboratory systems strengthening community of practice (LabCoP) initiative. Out of a target of 15 countries, 12 countries have ongoing or completed analyses using OptiDx-network optimization software co-developed by FIND to support resource planning for national laboratory systems-for TB, TB/HIV, and associated molecular testing. The capacity building of country teams in the use of OptiDx continues in several countries, including Cote d'Ivoire, India, and Zambia. Two strategic DNO analyses are underway, in Kenya and Pakistan, which will likely inform key priorities, including planning for Global Fund support, and integrated disease testing. FIND also developed an online DNO course, aimed at strategic decision-makers, in which 393 participants from 30 countries participated. DNO analyses in countries have focused on identifying gaps in testing capacity and strategies needed to expand testing in hard-to-reach areas.

    Expenses $6,560,663 · Grants $3,736,744

As filed on the 2022 return. The filer continues this part on Schedule O, which is not shown here.

Listed in Part VII

  • William Rodriguez

    Chief Executive Officer

    Total calculated
    $421,585
    From this org
    $323,816
    From related orgs
    $0
    Other
    $97,769
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $308,730
    Bonus
    $15,086
    Other
    $0
    Deferred
    $67,143
    Nontaxable benefits
    $30,626
    Filer's total
    $421,585
  • Sergio Carmona

    CHIEF MEDICAL OFFICER

    Total calculated
    $392,367
    From this org
    $328,189
    From related orgs
    $0
    Other
    $64,178
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $319,622
    Bonus
    $8,567
    Other
    $0
    Deferred
    $60,016
    Nontaxable benefits
    $4,162
    Filer's total
    $392,367
  • Louisa Chaubert

    Director of Finance

    Total calculated
    $330,220
    From this org
    $270,419
    From related orgs
    $0
    Other
    $59,801
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $261,852
    Bonus
    $8,567
    Other
    $0
    Deferred
    $53,506
    Nontaxable benefits
    $6,295
    Filer's total
    $330,220
  • Emma Jane Hannay

    Chief Access Officer

    Total calculated
    $309,104
    From this org
    $254,174
    From related orgs
    $0
    Other
    $54,930
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $245,553
    Bonus
    $8,621
    Other
    $0
    Deferred
    $54,930
    Nontaxable benefits
    $0
    Filer's total
    $309,104
  • Willo Brock start 922

    VP,external Affairs

    Total calculated
    $301,537
    From this org
    $273,739
    From related orgs
    $0
    Other
    $27,798
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $262,155
    Bonus
    $11,584
    Other
    $0
    Deferred
    $22,213
    Nontaxable benefits
    $5,585
    Filer's total
    $301,537
  • Daniel Bausch

    sr. advisor, global health sec

    Total calculated
    $291,827
    From this org
    $231,901
    From related orgs
    $0
    Other
    $59,926
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $223,334
    Bonus
    $8,567
    Other
    $0
    Deferred
    $48,289
    Nontaxable benefits
    $11,637
    Filer's total
    $291,827
  • Marta Fernandez Suarez

    Chief Technology Officer

    Total calculated
    $288,781
    From this org
    $252,721
    From related orgs
    $0
    Other
    $36,060
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $242,005
    Bonus
    $10,716
    Other
    $0
    Deferred
    $20,461
    Nontaxable benefits
    $15,599
    Filer's total
    $288,781
  • Morten Ruhwald

    Director, TB Programme

    Total calculated
    $283,058
    From this org
    $230,800
    From related orgs
    $0
    Other
    $52,258
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $219,431
    Bonus
    $11,369
    Other
    $0
    Deferred
    $42,050
    Nontaxable benefits
    $10,208
    Filer's total
    $283,058
  • Sharon Saacks

    DIRECTOR OF OPERATIONS

    Total calculated
    $277,715
    From this org
    $219,034
    From related orgs
    $0
    Other
    $58,681
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $210,467
    Bonus
    $8,567
    Other
    $0
    Deferred
    $47,288
    Nontaxable benefits
    $11,393
    Filer's total
    $277,715
  • Beatrice Mouton

    Director, Human Resources

    Total calculated
    $266,716
    From this org
    $224,498
    From related orgs
    $0
    Other
    $42,218
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $215,931
    Bonus
    $8,567
    Other
    $0
    Deferred
    $42,218
    Nontaxable benefits
    $0
    Filer's total
    $266,716
  • Stefano Ongarello

    Director, Data Science

    Total calculated
    $256,743
    From this org
    $207,805
    From related orgs
    $0
    Other
    $48,938
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $201,647
    Bonus
    $6,158
    Other
    $0
    Deferred
    $39,505
    Nontaxable benefits
    $9,433
    Filer's total
    $256,743
  • Sylvain Bieler

    Senior Scientist

    Total calculated
    $253,990
    From this org
    $213,699
    From related orgs
    $0
    Other
    $40,291
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $205,385
    Bonus
    $8,314
    Other
    $0
    Deferred
    $40,291
    Nontaxable benefits
    $0
    Filer's total
    $253,990
  • Sanjay Sarin

    VP, ACCESS

    Total calculated
    $236,562
    From this org
    $236,562
    From related orgs
    $0
    Other
    $0
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $228,000
    Bonus
    $8,562
    Other
    $0
    Deferred
    $0
    Nontaxable benefits
    $0
    Filer's total
    $236,562
  • Aditi Srinivasan

    Director, Data Science

    Total calculated
    $233,937
    From this org
    $203,387
    From related orgs
    $0
    Other
    $30,550
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $198,511
    Bonus
    $4,876
    Other
    $0
    Deferred
    $30,550
    Nontaxable benefits
    $0
    Filer's total
    $233,937
  • Cassandra Kelly-Cirinostart922

    VP; Health Programmes

    Total calculated
    $97,076
    From this org
    $76,930
    From related orgs
    $0
    Other
    $20,146
    Hours/week
    40
  • MARK KESSEL end 1122

    CHAIRMAN OF THE BOARD

    Total calculated
    $0
    Hours/week
    1
  • Daniel Robert Camus

    MEMBER OF THE BOARD

    Total calculated
    $0
    Hours/week
    1
  • ANDREW JOHN JACK end 1122

    MEMBER OF THE BOARD

    Total calculated
    $0
    Hours/week
    1
  • Iona Kickbush

    Member of the Board

    Total calculated
    $0
    Hours/week
    1
  • Carlos Morel Medicis

    Member of the Board

    Total calculated
    $0
    Hours/week
    1
  • Marcel Tanner

    Member of the Board

    Total calculated
    $0
    Hours/week
    1
  • SHEILA TLOU end 922

    Member of the Board

    Total calculated
    $0
    Hours/week
    1
  • MICHAEL WATSON end 922

    Member of the Board

    Total calculated
    $0
    Hours/week
    1
  • David Heymann

    Member of the Board

    Total calculated
    $0
    Hours/week
    1
  • GAO FU end 922

    Member of the Board

    Total calculated
    $0
    Hours/week
    1
  • Kamineni Shobana

    Member of the Board

    Total calculated
    $0
    Hours/week
    1
  • Frutiger Christian

    BOARD MEMBER

    Total calculated
    $0
    Hours/week
    1
  • Ayoade Alakija start 1122

    Chairman of the Board

    Total calculated
    $0
    Hours/week
    1
  • Soumya Swaminathanstart1122

    Member of the Board

    Total calculated
    $0
    Hours/week
    1
  • Precious Matsoso start 1122

    member of the board

    Total calculated
    $0
    Hours/week
    1

Compensation is as filed in Part VII: reportable pay from this organization and from related organizations, other compensation, and hours per week. The total, marked calculated, is our sum of the three dollar columns, with a blank column counted as $0; the form itself has no total. On a Form 990-EZ the columns are Part IV's instead, and on a Form 990-PF Part VIII's — compensation, contributions to benefit plans, and expense account — and the total sums those. A Schedule J breakdown is as filed: base pay, bonus, other, deferred compensation and nontaxable benefits from this organization, with any from related organizations beside each, and the filer's own total. It is shown with the Part VII listing of the same name on the same return. The form gives no key between the two, so that pairing is ours, and is marked matched by us.

Schedule J

Answered yes

  • 3 · Compensation committee

Answered no

  • 4a · Severance or change-of-control payment
  • 4b · Supplemental nonqualified retirement plan
  • 4c · Equity-based compensation arrangement
  • 5a · Pay contingent on this organization's revenues
  • 5b · Pay contingent on a related organization's revenues
  • 6a · Pay contingent on this organization's net earnings
  • 6b · Pay contingent on a related organization's net earnings
  • 7 · Other non-fixed payments
  • 8 · Paid under the initial-contract exception

Part I's answers as filed. A line not listed was left unanswered; on lines 1a and 3 that means the box was not checked.

Grants on this return

  • Biomeme

    $4,015,000

    Development of diagnostic tests

  • Transnational TechnologiesInc

    $3,200,000

    Supportmanufacturingandcommercializationof antigenrdtforcovid

  • WHO-PAHO

    $2,275,676

    Scaling-uptheuseofcovidantigenrapiddiagnost ic tests in Americas testsinAmericas testsinAmericas

  • TosupportTBeliminationefforts

  • DiagnosticConsultingNetworkInc

    $854,249

    Developmentofdiagnostictests

  • Elizabeth Glaser Pediatric Aids Foundation

    $793,500

    Evaluation of Antigen Rapid Diagnostic Tests

  • ImplementationofcovidagRDTsinSouthSudan

  • Sponsored Research

  • Laboratorystrengtheningtosupportclinicalcare andresearch

  • ManagementSciencesforHealth

    $621,481

    Undertake a project in the field of in vitro diagnostics and COVID

The 10 largest by cash amount. The API serves every itemized grant.

Activities outside the United States

From Schedule F of this return, as filed.

Offices (line 3c)
3
Employees, agents and contractors (line 3c)
129
Expenditures and investments (line 3c)
$122,280,114

At most 25 lines of each part are listed here. Schedule F names no grantee, so each line is a region and its money.

Activities by region (Part I)

Region Offices Employees Activity Specific services Expenditures
Sub-Saharan Africa 1 4 Program Services SEE PART V $24,292,340
South Asia 0 2 Program Services See Part V $5,423,718
East Asia and the Pacific 1 7 Program Services See Part V $22,172,364
Europe (Including Iceland and Greenland) 1 116 Program Services See Part V $63,637,622
South America 0 0 Program Services See Part V $3,774,608
North America 0 0 Program Services See Part V $676,041
Russia and the Newly Independent States 0 0 Program Services See Part V $1,246,649
Middle East and North Africa 0 0 Program Services See Part V $251,485
Central America and the Caribbean 0 0 Program Services See Part V $805,287

Grants to organizations, by region (Part II)

The purpose of each grant is not shown.

Region Cash grants Manner of disbursement Noncash assistance Noncash description Valuation
Sub-Saharan Africa $17,684,107 ELEC FD TRAN — N/A N/A
South Asia $1,937,978 ELEC FD TRAN — N/A N/A
East Asia and the Pacific $18,066,911 ELEC FD TRAN — N/A N/A
Europe (Including Iceland and Greenland) $26,938,776 ELEC FD TRAN — N/A N/A
South America $3,331,496 ELEC FD TRAN — N/A N/A
North America $215,853 ELEC FD TRAN — N/A N/A
Russia and the Newly Independent States $903,809 ELEC FD TRAN — N/A N/A
Middle East and North Africa $43,893 ELEC FD TRAN — N/A N/A
Central America and the Caribbean $762,468 ELEC FD TRAN — N/A N/A
Grantees recognized as charities or with a 501(c)(3) equivalency letter (Part II line 2)
131
Other grantees (Part II line 3)
217
Transferred property to a foreign corporation during the year (line 1)
No
Had an interest in a foreign trust (line 2)
No
Owned an interest in a foreign corporation (line 3)
No
Was a shareholder of a passive foreign investment company or qualified electing fund (line 4)
No
Owned an interest in a foreign partnership (line 5)
No
Had operations in or related to a boycotting country (line 6)
No

Related organizations on this return

Schedule R Part II: tax-exempt organizations related to the filer by control. It does not record shared board members or money.

  • FIND INDIA

    n/a · PROGRAM SVCS · IN · controlled entity

    Directly controlled by FIND SWISS

  • FIND DX NPC

    n/a · PROGRAM SVCS · SF · controlled entity

    Directly controlled by FIND SWISS

  • FIND DX KENYA

    n/a · PROGRAM SVCS · KE · controlled entity

    Directly controlled by FIND SWISS

Provenance

Return type
form_990
Tax year
2022
Filed
15 November 2023
IRS schema version
2022v5.0
Source object
202343199349316034

Check it against the return as filed: the GivingTuesday Data Lake hosts a public copy of the original XML.

The source document this was parsed from is served over the API, which is where bulk and document access live.